Association between clinical stage of oral cancer and expression of immunohistochemical markers

Świątkowski, Wojciech; Rahnama-Hezavah, Mansur; Tomaszewski, Tomasz; Bigas, M. A. Rodriguez; Swiaţkowska, A; Łobacz, Michał; Wallner, J.

doi:10.5604/01.3001.0010.6736

Cited by 3 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To assess the recurrence in OSCC, sundry cell proliferative markers are used alone or in amalgamation [ Table 1 ]. Included studies used p53 in four studies[ 4 5 6 7 ] in combination with p44/p42, proliferating cell nuclear antigen (PCNA), epidermal growth factor receptor (EGFR) in OSCC[ 1 ] while with Ki-67, Bcl2 in oral leukoplakia and OSCC. [ 2 ] Cyclin B1 was used in one study,[ 3 ] AgNORs in two studies in OSCC[ 3 4 ] and one study in oral leukoplakia five and OSCC, Nibrin in OSCC,[ 8 ] Ki67 was used in eight studies along with AgNORs,[ 9 10 11 12 13 ] cornulin, ISG15 in OSCC,[ 14 15 ] MCMC-2[ 16 ] and three studies in oral leukoplakia and OSCC p53 from DAKO was used in dilution, 1:50 in one study along with PCNA (clone PC10) in dilution, 1:5000, phospho-p44/p42 mitogen-activated protein kinase (ERK1/ERK2; Cell-Signaling, Technology R; dilution, 1:100, EGFR Ab-10, clone 111.6; Thermo Scientific; dilution, 1:100).…”

Section: Resultsmentioning

confidence: 99%

“…All gave brown staining to the nucleus of epithelial cells. [ 1 ] In another study, p53 was used with Ki-67 as p53 (BP-53-12, PM 101-6ML), and Ki-67 (GM 001-PM 096-6ML) from Gene Pulse Scientific[ 2 ]. p53 and Ki-67 were both ready to use antibodies procured from BioGenex while Bcl2 was also ready to use from Biocare Medical.…”

Section: Resultsmentioning

confidence: 99%

“…A local recurrence or metastasis affects more than 50% of patients ultimately, usually within the first two years after therapy is finished. [ 1 ]…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Role of proliferative markers in assessing recurrences in surgical margins of oral squamous cell carcinoma: A systematic review

Gawande,

Khan,

Sharma

et al. 2023

Journal of Oral and Maxillofacial Pathology

View full text Add to dashboard Cite

The primary goal of this systematic analysis is to determine the predictive significance of proliferative markers in surgical margins of patients with oral squamous cell carcinoma (OSCC). A thorough literature search was done on databases like MEDLINE/Pub-Med, Cochrane and Scopus libraries for similar studies until December 2022. All the relevant original research studies (retrospective and prospective) published in the literature assessing the predictive value of proliferative markers in surgical margins in OSCC were included. Seventeen studies with 1159 patients were included. The research included here used p53, p44/p42, proliferating cell nuclear antigen (PCNA), epidermal growth factor receptor (EGFR), Ki-67, Bcl2, Nibrin, AgNORs, Cyclin B1, Cornulin, ISG 15antibodies, MCM3 in OSCC. Four studies were done on oral premalignant lesions and OSCC. Among these studies, Ki-67 was the most accurate, followed by p53 (75%) and AgNORs, while PCNA had the least accuracy. To minimize the risk of bias panel of antibodies was suggested in most studies. For interobserver variability, analysis of variance and Chi-square test were used in most studies. The chance of recurrence rate was calculated using a log-rank test and a Kaplan–Meier curve. The significance of proliferative markers in surgical margins of OSCC has been emphasized in the present review. Future research should focus on selecting antibodies, preferably a panel, with a large sample size and extended follow-up.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Role of proliferative markers in assessing recurrences in surgical margins of oral squamous cell carcinoma: A systematic review

Gawande,

Khan,

Sharma

et al. 2023

Journal of Oral and Maxillofacial Pathology

View full text Add to dashboard Cite

show abstract

“…Epidermal growth factor receptor (EGFR) belongs to the Human Epidermal Growth Factor Receptor (HER) family of transmembrane receptors with tyrosine kinase activity, which are overexpressed in more than 90% of squamous cell carcinoma of the head and neck (HNSCC) 11,12 . Numerous studies indicate increased expression and activity of membrane EGFR (mEFGR) in OPMD and OSCC, with the degree of expression dependent on the severity of the disease 13,14 . Overexpression of EGFR in HNSCC has a negative impact on local disease control and survival 15,16 .…”

Section: Introductionmentioning

confidence: 99%

“…11,12 Numerous studies indicate increased expression and activity of membrane EGFR (mEFGR) in OPMD and OSCC, with the degree of expression dependent on the severity of the disease. 13,14 Overexpression of EGFR in HNSCC has a negative impact on local disease control and survival. 15,16 Although the role of mEGFR in HNSCC is well established and a number of anti-EGFR therapies have been developed and are routinely used, we often see poor response to therapy and resistance.…”

mentioning

confidence: 99%

Significance of nuclear EGFR and ABCG2 expression in malignant transformation of oral potentially malignant disorders

et al. 2022

View full text Add to dashboard Cite

Background The purpose of this study was to investigate the expression of nuclear EGFR (nEGFR) and the stem cell marker ABCG2 in oral leukoplakia (OL) and oral erythroplakia (OE) and to assess their significance as prognostic biomarkers for malignant transformation. Methods In this study we included 50 patients with oral potentially malignant disorders (OPMD), 31 with OL and 19 with OE, in whom we examined the expression of nEGFR and ABCG2 by immunohistochemical methods. Results Twenty‐one (42%) of 50 patients with OL and OE developed oral squamous cell carcinoma (OSCC). The malignant transformation was increased 12,84‐fold (95% CI, 2.15–76.44, p = 0.005) in OPMD expressing both ABCG2 and nEGFR. Expression of nEGFR is a strong indicator of malignant transformation, unlike ABCG2 expression, respectively. Conclusions Determining the co‐expression of the biomarkers nEGFR and ABCG2 in OPMD may serve us to determine the risk of malignant transformation in OSCC.

show abstract

A systematic review of proteomic biomarkers in oral squamous cell cancer

et al. 2021

View full text Add to dashboard Cite

Background Head and neck squamous cell cancer (HNSCC) is the most common cancer associated with chewing tobacco, in the world. As this is divided in to sites and subsites, it does not make it to top 10 cancers. The most common subsite is the oral cancer. At the time of diagnosis, more than 50% of patients with oral squamous cell cancers (OSCC) had advanced disease, indicating the lack of availability of early detection and risk assessment biomarkers. The new protein biomarker development and discovery will aid in early diagnosis and treatment which lead to targeted treatment and ultimately a good prognosis. Methods This systematic review was performed as per PRISMA guidelines. All relevant studies assessing characteristics of oral cancer and proteomics were considered for analysis. Only human studies published in English were included, and abstracts, incomplete articles, and cell line or animal studies were excluded. Results A total of 308 articles were found, of which 112 were found to be relevant after exclusion. The present review focuses on techniques of cancer proteomics and discovery of biomarkers using these techniques. The signature of protein expression may be used to predict drug response and clinical course of disease and could be used to individualize therapy with such knowledge. Conclusions Prospective use of these markers in the clinical setting will enable early detection, prediction of response to treatment, improvement in treatment selection, and early detection of tumor recurrence for disease monitoring. However, most of these markers for OSCC are yet to be validated.

show abstract

Association between clinical stage of oral cancer and expression of immunohistochemical markers

Abstract: Looking for oral squamous cell carcinoma markers remains an actual issue. Identification of specific markers of oral cancer could be used in screening the population, determining prognosis and response to treatment.

Cited by 3 publications

References 9 publications

Role of proliferative markers in assessing recurrences in surgical margins of oral squamous cell carcinoma: A systematic review

Role of proliferative markers in assessing recurrences in surgical margins of oral squamous cell carcinoma: A systematic review

Significance of nuclear EGFR and ABCG2 expression in malignant transformation of oral potentially malignant disorders

A systematic review of proteomic biomarkers in oral squamous cell cancer

Contact Info

Product

Resources

About